AbbVie stock at USD 264.40 on September 25, 2026, down 0.27 percent
Published on 09/28/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Ahead of the next regular session, AbbVie Inc. stock was last quoted at USD 264.40 on the New York Stock Exchange at 20:00 UTC on September 25, 2026. The price was down 0.27 percent from the prior session.
September 25 trading reference
The reference session ended before the publication date of September 28, 2026. The quote is presented separately from AbbVie’s earlier company announcement and does not establish a connection between the stock performance and that announcement.
European approval for RINVOQ
On September 22, 2026, AbbVie said the European Commission approved RINVOQ, or upadacitinib, for active polyarticular juvenile idiopathic arthritis in patients two years of age and older who had responded inadequately to, or were intolerant to, one or more disease-modifying anti-rheumatic drugs. The approval covers a 15 mg tablet and a weight-based 1 mg/mL oral solution. PR Newswire identified AbbVie as the issuer of the announcement.
AbbVie said RINVOQ may be used as monotherapy or in combination with methotrexate for the new indication. The company reported that the European approval was supported by the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis. The release said RINVOQ was approved in the European Union for 11 indications across immune-mediated and inflammatory diseases. The company release provided the clinical and regulatory details.
